Turmeric is one the most thoroughly researched plants in existence
today. Its medicinal properties and components (primarily curcumin)
have been the subject of over 5600 peer-reviewed and published
biomedical studies. In fact, our five-year long research project on
this sacred plant has revealed over 600 potential preventive and
therapeutic applications, as well as 175 distinct beneficial
physiological effects. This entire database of 1,585 ncbi-hyperlinked
turmeric abstracts can be downloaded as a PDF at our Downloadable
Turmeric Document page, and acquired either as a retail item or with
200 GMI-tokens, for those of you who are already are members and
receive them automatically each month.
Given the sheer density of research performed on this remarkable
spice, it is no wonder that a growing number of studies have concluded
that it compares favorably to a variety of conventional medications,
including:
Lipitor/Atorvastatin(cholesterol medication): A 2008 study published
in the journal Drugs in R & D found that a standardized preparation of
curcuminoids from Turmeric compared favorably to the drug atorvastatin
(trade name Lipitor) on endothelial dysfunction, the underlying
pathology of the blood vessels that drives atherosclerosis, in
association with reductions in inflammation and oxidative stress in
type 2 diabetic patients. [i] [For addition curcumin and 'high
cholesterol' research – 8 abstracts]
Corticosteroids (steroid medications): A 1999 study published in the
journal Phytotherapy Research found that the primary polyphenol in
turmeric, the saffron colored pigment known as curcumin, compared
favorably to steroids in the management of chronic anterior uveitis,
an inflammatory eye disease.[ii] A 2008 study published in Critical
Care Medicine found that curcumin compared favorably to the
corticosteroid drug dexamethasone in the animal model as an
alternative therapy for protecting lung transplantation-associated
injury by down-regulating inflammatory genes.[iii] An earlier 2003
study published in Cancer Letters found the same drug also compared
favorably to dexamethasone in a lung ischaemia-repurfusion injury
model.[iv] [for additional curcumin and inflammation research – 52
abstracts]
Prozac/Fluoxetine & Imipramine (antidepressants): A 2011 study
published in the journal Acta Poloniae Pharmaceutica found that
curcumin compared favorably to both drugs in reducing depressive
behavior in an animal model.[v] [for additional curcumin and
depression research – 5 abstracts]
Aspirin (blood thinner): A 1986 in vitro and ex vivo study published
in the journal Arzneimittelforschung found that curcumin has anti-
platelet and prostacyclin modulating effects compared to aspirin,
indicating it may have value in patients prone to vascular thrombosis
and requiring anti-arthritis therapy.[vi] [for additional curcumin
and anti-platelet research]
Anti-inflammatory Drugs: A 2004 study published in the journal
Oncogene found that curcumin (as well as resveratrol) were effective
alternatives to the drugs aspirin, ibuprofen, sulindac,
phenylbutazone, naproxen, indomethacin, diclofenac, dexamethasone,
celecoxib, and tamoxifen in exerting anti-inflammatory and anti-
proliferative activity against tumor cells.[vii] [for additional
curcumin and anti-proliferative research – 15 abstracts]
Oxaliplatin (chemotherapy drug): A 2007 study published in the
International Journal of Cancer found that curcumin compares favorably
with oxaliplatin as an antiproliferative agenet in colorectal cell
lines.[viii] [for additional curcumin and colorectal cancer research –
52 abstracts]
Metformin (diabetes drug): A 2009 study published in the journal
Biochemitry and Biophysical Research Community explored how curcumin
might be valuable in treating diabetes, finding that it activates AMPK
(which increases glucose uptake) and suppresses gluconeogenic gene
expression (which suppresses glucose production in the liver) in
hepatoma cells. Interestingly, they found curcumin to be 500 times to
100,000 times (in the form known as tetrahydrocurcuminoids(THC)) more
potent than metformin in activating AMPK and its downstream target
acetyl-CoA carboxylase (ACC). [ix]
Another way in which turmeric and its components reveal their
remarkable therapeutic properties is in research on drug resistant-
and multi-drug resistant cancers. We have two sections on our site
dedicated to researching natural and integrative therapies on these
topics, and while there are dozens of substances with demonstrable
efficacy against these chemotherapy- and radiation-resistant cancers,
curcumin tops both lists:
Cancers: Drug Resistant
Cancers: Multi-Drug Resistant
We have found no less than 54 studies indicating that curcumin can
induce cell death or sensitize drug-resistant cancer cell lines to
conventional treatment.[x]
We have identified 27 studies on curcumin's ability to either induce
cell death or sensitize multi-drug resistant cancer cell lines to
conventional treatment.[xi]
Considering how strong a track record turmeric (curcumin) has, having
been used as both food and medicine in a wide range of cultures, for
thousands of years, a strong argument can be made for using curcumin
as a drug alternative or adjuvant in cancer treatment.
Or, better yet, use certified organic (non-irradiated) turmeric in
lower culinary doses on a daily basis so that heroic doses won't be
necessary later in life after a serious disease sets in. Nourishing
yourself, rather than self-medicating with 'nutraceuticals,' should be
the goal of a healthy diet. [learn more at Sayer Ji's new
collaborative project EATomology]
Resources
[i] P Usharani, A A Mateen, M U R Naidu, Y S N Raju, Naval Chandra.
Effect of NCB-02, atorvastatin and placebo on endothelial function,
oxidative stress and inflammatory markers in patients with type 2
diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-
week study. Drugs R D. 2008;9(4):243-50. PMID: 18588355
[ii] B Lal, A K Kapoor, O P Asthana, P K Agrawal, R Prasad, P Kumar, R
C Srimal. Efficacy of curcumin in the management of chronic anterior
uveitis. Phytother Res. 1999 Jun;13(4):318-22. PMID: 10404539
[iii] Jiayuan Sun, Weigang Guo, Yong Ben, Jinjun Jiang, Changjun Tan,
Zude Xu, Xiangdong Wang, Chunxue Bai. Preventive effects of curcumin
and dexamethasone on lung transplantation-associated lung injury in
rats. Crit Care Med. 2008 Apr;36(4):1205-13. PMID: 18379247
[iv] J Sun, D Yang, S Li, Z Xu, X Wang, C Bai. Effects of curcumin or
dexamethasone on lung ischaemia-reperfusion injury in rats. Cancer
Lett. 2003 Mar 31;192(2):145-9. PMID: 18799504
[v] Jayesh Sanmukhani, Ashish Anovadiya, Chandrabhanu B Tripathi.
Evaluation of antidepressant like activity of curcumin and its
combination with fluoxetine and imipramine: an acute and chronic
study. Acta Pol Pharm. 2011 Sep-Oct;68(5):769-75. PMID: 21928724
[vi] R Srivastava, V Puri, R C Srimal, B N Dhawan. Effect of curcumin
on platelet aggregation and vascular prostacyclin synthesis.
Arzneimittelforschung. 1986 Apr;36(4):715-7. PMID: 3521617
[vii] Yasunari Takada, Anjana Bhardwaj, Pravin Potdar, Bharat B
Aggarwal. Nonsteroidal anti-inflammatory agents differ in their
ability to suppress NF-kappaB activation, inhibition of expression of
cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell
proliferation. Oncogene. 2004 Dec 9;23(57):9247-58. PMID: 15489888
[viii] Lynne M Howells, Anita Mitra, Margaret M Manson. Comparison of
oxaliplatin- and curcumin-mediated antiproliferative effects in
colorectal cell lines. Int J Cancer. 2007 Jul 1;121(1):175-83. PMID:
17330230
[ix] Teayoun Kim, Jessica Davis, Albert J Zhang, Xiaoming He, Suresh T
Mathews. Curcumin activates AMPK and suppresses gluconeogenic gene
expression in hepatoma cells. Biochem Biophys Res Commun. 2009 Oct
16;388(2):377-82. Epub 2009 Aug 8. PMID: 19665995
[x] GreenMedInfo.com, Curcumin Kills Drug Resistant Cancers, 54
Abstracts
[xi] GreenMedInfo.com, Curcumin Kills Multi-Drug Resistant Cancers: 27
Abstracts.
SOURCE:
http://www.greenmedinfo.com/blog/science-confirms-turmeric-effective-14-drugs